Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5741717 | 0.86 | GSK3B (0.54) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2488656 | 0.77 | GSK3B (0.55) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2490246 | 0.77 | GSK3B (0.60) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2487968 | 0.76 | GSK3B (0.54) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL695979 | 0.75 | GSK3B (0.72) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2488292 | 0.75 | GSK3B (0.47) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL5741788 | 0.74 | MAPK14 (0.42) | — | |
| SCHEMBL8344197 | 0.74 | GSK3B (0.60) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2490162 | 0.74 | GSK3B (0.47) | GSK3BCYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL697107 | 0.74 | GSK3B (0.71) | GSK3BCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049318-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-05-23 | — | — | US | disclosed |
| EP-1654250-A1 | SUBSTITUTED PYRIDONES AND PYRIMIDINONES WITH ANTIINFLAMMATORY PROPERTIES | AMGEN INC. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005012286-A1 | SUBSTITUTED PYRIDONES AND PYRIMIDINONES WITH ANTIINFLAMMATORY PROPERTIES | AMGEN INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050020592-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020592-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | GSK3B 205/4885CYP1A2 1295/4885CYP2D6 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.